# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Header</td>
<td>1</td>
</tr>
<tr>
<td>Abstract</td>
<td>1</td>
</tr>
<tr>
<td>Background</td>
<td>1</td>
</tr>
<tr>
<td>Objectives</td>
<td>3</td>
</tr>
<tr>
<td>Methods</td>
<td>3</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>9</td>
</tr>
<tr>
<td>References</td>
<td>10</td>
</tr>
<tr>
<td>Appendices</td>
<td>14</td>
</tr>
<tr>
<td>Contributions of Authors</td>
<td>14</td>
</tr>
<tr>
<td>Declarations of Interest</td>
<td>14</td>
</tr>
<tr>
<td>Sources of Support</td>
<td>14</td>
</tr>
</tbody>
</table>
Couple and family therapies for post-traumatic stress disorder (PTSD)

Sean Cowlishaw¹ ², Lynette Evans³, Aino Suomi², Bryan Rodgers²

¹Centre for Academic Primary Care, School of Social and Community Medicine, University of Bristol, Bristol, UK. ²School of Sociology, ANU College of Arts and Social Sciences, Australian National University, Canberra, Australia. ³School of Psychological Science, Faculty of Science, Technology and Engineering, La Trobe University, Melbourne, Australia

Contact address: Sean Cowlishaw, Centre for Academic Primary Care, School of Social and Community Medicine, University of Bristol, Canygne Hall, 39 Whatley Road, Bristol, BS8 2PS, UK. sean.cowlishaw@bristol.ac.uk. sean.cowlishaw@gmail.com.

Editorial group: Cochrane Common Mental Disorders Group.


ABSTRACT

This is the protocol for a review and there is no abstract. The objectives are as follows:

The objectives of this review will be to:

1. assess the efficacy of couple and family therapies for adult PTSD, relative to 'no treatment' conditions, 'standard care', and structured or non-specific individual psychological therapies;
2. examine the clinical characteristics of studies that influence the relative efficacy of these therapies; and
3. critically evaluate methodological features of studies that bias research findings.

BACKGROUND

Description of the condition

Post-traumatic stress disorder (PTSD) refers to an anxiety or trauma and stressor related disorder where symptom onset is linked to personal or vicarious exposure to traumatic events. These include events characterised by death or threatened death, sexual violence, as well as actual or threatened serious injury (American Psychiatric Association 2013). The previous fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV TR) (American Psychiatric Association 2000), which is most commonly used in currently available research, defines three categories of psychiatric symptoms that may indicate a diagnosis of PTSD. These include:

1. intrusive re-experiencing of the event (e.g., through flashbacks and dreams);
2. avoidance of reminders and emotional numbing; and
3. persistent high levels of arousal and reactivity (e.g., hypervigilance to threat).

These symptom clusters have been re-organised in the recent fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (American Psychiatric Association 2013), which now identifies four categories of PTSD symptoms:
1. intrusion;
2. avoidance;
3. negative alterations in cognitions and mood; and
4. alterations in arousal and reactivity.

The revised system thus re-positions emotional numbing in a category that also includes negative cognitions (e.g., self-blame) and emotions, while arousal symptoms are repositioned in a category including irritable and reckless or self-destructive behaviour (the latter are new symptoms). Notwithstanding these revisions, the fundamental construct built into the updated criteria is unchanged (Friedman 2011), whereby close comparability between DSM-IV and DSM-5 diagnoses is expected (Regier 2013). Current data suggest a lifetime prevalence of PTSD around 8% in the general population (Kessler 1995), and indicates a disorder that often follows a chronic course (Orcutt 2004; Solomon 2006). PTSD is also associated with a range of adverse individual outcomes (e.g., poor health, suicidality) (Sareen 2007), as well as significant interpersonal problems, including difficulties in intimate and family relationships (Taft 2011).

Most evidence linking PTSD to family problems is derived from studies of military veterans, from Europe and the United States, which document associations among post-traumatic symptoms and various adverse relationship outcomes (Galovski 2004). These include low relationship satisfaction (Goff 2007), family violence (Glenn 2002), and family members’ own mental health problems (Jordan 1992). Comparative investigations of other trauma populations are relatively few, but also suggest links between PTSD and problems in intimate relationships. For example, studies following natural disasters indicate relations between post-traumatic symptoms and poor relationship adjustment (e.g., Taft 2009), while PTSD following interpersonal victimisation predicts family violence (e.g., Krause 2006). Studies of survivors of childhood sexual abuse also suggest problems with intimate relationships in adulthood (e.g., Cloitre 1997; Lamoureux 2012), including specific difficulties with intimacy and sexual dysfunction (Davis 2000). However, the unique influences of PTSD in the development of these long-term problems remain poorly understood.

The inter-relations among PTSD and family problems are likely to be complex, reflecting both the impact of post-traumatic symptoms on other family members, and effects of the family environment on PTSD. On the one hand, avoidance symptoms may reduce involvement in family activities, while emotional numbing can inhibit self-disclosure and intimacy (Erbes 2008). Hyperarousal symptoms are linked to irritability and anger and can also precipitate aggression and family conflict (Taft 2007a; Taft 2007b). On the other hand, prospective studies of veterans show that family relationships can predict change in PTSD (Evans 2009; Evans 2010), whereby an adaptive family environment can reduce the severity of symptoms, or exacerbate problems if interpersonal patterns are dysfunctional. These inter-relations are likely to be particularly complex when PTSD is linked to certain types of trauma. These may include interpersonal trauma (e.g., sexual assault), where relationships (including family relationships) are associated with the traumatic event and the onset of symptoms, as well as other events (e.g., natural disasters, motor vehicle accidents) which impact directly on multiple family members simultaneously (Riggs 2009).

**Description of the intervention**

Evidence of associations among post-traumatic symptoms and family difficulties has provided impetus for consideration of couple and family therapies for PTSD. General reviews of literature on couple therapies, such as Baucom 1998 and Snyder 2006, distinguish two main classes of couple-based interventions (and by extension, therapies working with broader family systems) when used for individual mental health problems. These include (1) generic therapies, developed to treat distressed relationships and address common interpersonal problems that can exacerbate individual symptoms, and (2) disorder-specific interventions, targeting interactions between interpersonal processes and specific symptoms of the disorder or its treatment.

Snyder 2006 describes several classes of generic therapies for distressed relationships that are often considered in clinical trials. First among these are behavioural therapies (e.g., traditional behavioural couple therapy) (Christensen 2004), which comprise techniques for enhancing family members’ relationship skills in problem solving and communication, and increasing the frequency of positive interactions. Second are therapies based on psychodynamic and attachment theory perspectives (e.g., insight oriented marital therapy) (Snyder 1989), that are characterised by a broad focus on developing awareness and expression of unknown feelings, thoughts and needs that may underlie interpersonal patterns (Baucom 1998). Other generic therapies are also available (although considered less often in clinical trials) (Snyder 2006), and can include cognitive strategies for changing ways of thinking about behaviours and relationships, as well as techniques for enhancing emotional acceptance. Another general class of interventions may include ‘systemic’ therapies (Coulter 2013), potentially including structural and strategic family therapies that focus on changing patterns of family interaction and organisation (Madanes 1981; Minuchin 1974). Integrative therapies draw from multiple conceptual models (Lebow 1997).

A number of disorder-specific couple and family therapies for PTSD have also been proposed and are reviewed by Riggs 2009. They include therapies based on behavioural principles and others grounded in cognitive-behavioural models or attachment theory (Figley 1988; Johnson 1998; Monson 2004; Mueser 1995). These targeted therapies are commonly oriented towards reducing partners’ distress or dysfunction in the couple relationship, as well as promoting improvements in individual PTSD. Monson 2004, for example, propose a stand-alone cognitive-behavioural treatment for post-traumatic symptoms and relationship functioning that consists of several stages of therapy. These initially de-
liver psycho-education about PTSD and relationship functioning, and also include behavioural interventions (e.g., communication skills training) to address avoidance and emotional numbing in the context of relationships. Subsequent stages comprise scheduled activities to reduce experiential avoidance and increase positive couple experiences, as well as dyadic cognitive interventions that target cognitions maintaining PTSD and relationship problems (Brown-Bowers 2012). Alternative interventions comprise adjunctive therapies that are delivered alongside other primary psychological and pharmacological treatments (Sautter 2009). Most of these interventions have been developed in the context of combat-related PTSD (Monson 2009), with a small number (such as emotionally focused therapy) proposed originally for use with victims of sexual or physical abuse (Johnson 1998), or with traumatised populations more generally (Figley 1988).

How the intervention might work

Given the complex inter-relations among post-traumatic symptoms and family adjustment, multiple mechanisms of change may underlie the proposed effects of couple and family therapies for PTSD. For example, interventions that enhance relationship skills (e.g., problem solving, communication) can equip families to manage interpersonal difficulties (e.g., associated with avoidance of social situations) and thus minimise frustrations and family conflicts that are linked to PTSD. Therapies which promote family members’ mutual understanding of post-traumatic symptoms and impacts on relationship dynamics (e.g., through increased sharing of experiences) might also assist in correcting erroneous beliefs about interpersonal behaviour (for example, a mistaken explanation for low affective involvement in terms of disengagement from the relationship, rather than emotional numbing), and further reduce family conflict. Interventions that enhance communication, or shared thoughts and feelings, may also facilitate enhanced self-disclosure and related experiences of emotional intimacy (Laurenceau 1998). These therapies will also operate through common factors shared across different interventions (e.g., positive expectancies of therapeutic change) (Sprengle 2004), and other processes that are relatively unique to specific clinical models; for example, emotionally focused therapy, which is argued to work, in part, by accessing and reprocessing negative affect that underlies dysfunctional patterns (Johnson 1998).

Improvements in individual functioning during therapy, including reductions in post-traumatic symptoms, are also expected to involve various mechanisms. In some instances, these individual benefits may result from the reduction of significant negative exchanges in family relationships (e.g., reflecting high levels of criticism, hostility and emotional over-involvement) that can act as psychosocial stressors and exacerbate PTSD symptoms (Tarrier 1999). Conversely, couple and family therapies may also promote symptom change by enabling family members to provide both comfort and social support; the latter of which predicts positive ad-

Why it is important to do this review

Despite growing research on the links between PTSD and the qualities of intimate and family relationships, there remains limited understanding of the efficacy of couple and family therapies for PTSD in adults. As far as can be ascertained, there is only one existing Cochrane systematic review that has considered family-based therapies (among others) for PTSD (Gilles 2012), and this review did not consider adult samples (but rather, focused on children and adolescents). Other Cochrane reviews of interventions for PTSD in adults have considered psychological therapies (Bisson 2007), pharmacological treatments (Stein 2006), as well as combined pharmacological and psychological interventions (Hetrick 2010). None of these have considered couple or family therapies. Other relevant Cochrane reviews have focused on prevention of PTSD and treatment of distress immediately (i.e., one to three months) following trauma exposure (Roberts 2009; Rose 2002). The currently proposed review will thus provide the first focused examination of best quality clinical trials of couple and family therapies for PTSD in adults.

OBJECTIVES

The objectives of this review will be to:

1. assess the efficacy of couple and family therapies for adult PTSD, relative to ‘no treatment’ conditions, ‘standard care’, and structured or non-specific individual psychological therapies;

2. examine the clinical characteristics of studies that influence the relative efficacy of these therapies; and

3. critically evaluate methodological features of studies that bias research findings.

METHODS

Criteria for considering studies for this review
Types of studies

Eligible studies will be randomised controlled trials (RCTs) of couple or family therapies for PTSD, or associated family difficulties, in adult samples. Cross-over trials are not expected in this context, but we will include them if couples or families are randomly allocated to treatment sequence. Cluster-randomised trials will also be eligible. We will not use sample size and language of the report to determine inclusion, and there will be no restrictions on the study settings that are eligible for the review. We will not consider quasi-randomised trials (using non-random forms of allocation to groups, such as sequential allocation) for inclusion.

Types of participants

Participants will be intact couples or families, comprised of family members of any ethnicity or sexual orientation, in which at least one adult family member (over the age of 18 years) meets criteria for PTSD. Consistent with Lebow 2012, we will define couples as “long-term committed unions of romantic partners whether or not these unions are recognised by the state”; thus including gay and lesbian and other long-standing relationships, irrespective of formal recognition as ‘married’. We will define a family as a couple with one or more children. In all cases one adult will be identified as suffering PTSD. It will be required that participants are diagnosed with PTSD according to recognised classification systems, including the International Classification of Diseases (ICD)-10 (WHO 2010), DSM-IV and DSM-5 (American Psychiatric Association 2000; American Psychiatric Association 2013). Assessment strategies considered appropriate for ascertainment of PTSD criteria will include general clinical interviews (e.g., based on DSM criteria) and structured clinical interviews (e.g., Clinician Administered PTSD Scale) (Blake 1995). We will also consider self-report assessment tools (e.g., PTSD Checklist; Weathers 1993) with validated clinical cut-offs.

Although we will consider studies of diverse family structures, it is expected that most participants will be adult couples who are intimate partners in marital or common law relationships. Studies where intimate partners are divorced or separated will not be considered. Studies of treatments for child or adolescent PTSD, or therapies that focus mainly on family violence are also out of scope.

Types of interventions

Experimental interventions

The review will consider any type of therapy that is intended to treat intact couples or families where at least one adult family member meets criteria for PTSD. We intend to evaluate several main categories of therapies as follows.

1. Cognitive-behavioural therapies: this category of interventions will include therapies based predominantly on behavioural and cognitive-behavioural approaches to treatment (Figley 1988; Monson 2004). Interventions based on pure cognitive approaches would also be classified under this category of therapy.

2. Psychodynamic therapies: this category of interventions will include therapies based predominantly on psychodynamic approaches to treatment. This may include emotion-focused and insight-oriented therapies (Johnson 1998; Snyder 1989).

3. Systemic therapies: this category of interventions will include therapies derived generally from general systems theory approaches to treatment (von Bertalanffy 1969). It will include structural therapies as well as strategic therapies, among others (Coulter 2013; Madanes 1981; Minuchin 1974), and interventions that draw from multiple systemic frameworks.

4. Integrative therapies: this category of interventions will include therapies that include components of treatment drawn from multiple conceptual models (Lebow 1997), including those listed above. Where potential integrative therapies are apparent, there will be initial efforts to classify the therapy as predominantly one type of treatment (where around 80% of sessions are dedicated to one component of treatment). Where it is not possible to classify one predominant type of treatment, the intervention will be classified as an integrative therapy.

We will consider additional categories of interventions as studies become available. Eligible therapies will be delivered as ‘stand-alone’ treatments, as well as ‘adjunctive’ therapies delivered in conjunction with other primary treatments (e.g., individual psychological therapy). We will include disorder-specific interventions developed for treatment of PTSD or associated family difficulties (Riggs 2009). We will also consider generic therapies for relationship discord that are delivered in the context of family members diagnosed with PTSD (Snyder 2006).

For the purpose of this review, it is required that interventions will be delivered by psychiatrists, psychologists, counsellors, nurses or other health professionals with specialist training in family therapy (including students under supervision). Our review scope is focused on therapies that work directly with intact couples or families and studies where patients mainly attend therapy sessions alone will not be considered.

Control conditions

The review will consider a range of control comparators including ‘no treatment’ controls, ‘standard care’, and structured or non-specific individual psychological therapies.

For the purpose of this review, no treatment control conditions will refer mainly to wait-list and assessment only controls. Standard care will refer to a heterogeneous category of existing treatments or clinical practices that may be non-specific and described variously as ‘existing practice’, ‘treatment as usual’ or ‘usual
care' (Freedland 2011). These may involve relatively rigorous conditions (e.g., standard of care). They might also comprise eclectic interventions including naturalistic prescribing of medications, or minor systemic components (e.g., family member psycho-education).

Structured or non-specific individual psychological therapies will include manualised individual therapies, such as those based on general approaches described in Types of interventions (e.g., cognitive-behavioural), and other therapies for PTSD (e.g., eye movement desensitisation and reprocessing) (Bisson 2007). Non-specific individual psychological therapies provide generic features of therapy, including clinical contact and human interaction (e.g., clinician warmth, empathy, social support), and a treatment rationale (Mohr 2009). As such, they may reflect practices that approximate supportive or humanistic therapy to varying degrees. The aim of this review is not to consider the superiority of different types of couple and family therapies. As such, we will exclude comparisons among alternative couple or family therapies as well as comparisons with partial treatment controls (e.g., the same couple or family intervention, minus key components of therapy that may drive therapeutic change).

We will also exclude studies that compare a couple or family therapy with an experimental pharmacological treatment (although comparisons with individual therapies that involve naturalistic prescribing of medications will be eligible).

Types of outcome measures

The current review will consider outcomes that address multiple domains of individual, couple and family adjustment. Additional outcomes, such as marital stability and observational measures of marital interaction, as well as potential adverse events (e.g., substance abuse, self-harm) may be considered in updates as studies and data become available.

Primary outcomes

1. Severity of PTSD symptoms, as demonstrated by the primary presenting patient and ascertained using self-reports or clinician reports on measurement scales such as the PTSD Checklist (Weathers 1993), the PTSD Symptom scale (Foal 1993), as well as the Clinician Administered PTSD Scale (Blake 1995); which is considered a gold standard measure in many contexts (Weathers 2001)

2. Severity of psychological symptoms of family members, ascertained using self-reports or clinician reports on measures of mental health symptom severity (e.g., PTSD Checklist; Weathers 1993) or psychological distress (e.g., the five-item Mental Health Index of the 36-item Short Form health survey (SF-36; Ware 2000). We will consider data from adult romantic partners and children in the family separately where sufficient data are available

3. Dyadic adjustment, ascertained using self-report, family member reports or clinician reports on measures of relationship satisfaction or distress, like the Dyadic Adjustment Scale or the Marital Adjustment Test (Locke 1959; Spanier 1976)

Secondary outcomes

4. Severity of co-occurring depression or anxiety, as demonstrated by the primary presenting patient and ascertained using self-reports or clinician reports on measurement scales such as the Beck Depression Inventory or the Beck Anxiety Inventory (Beck 1961; Beck 1988)

5. Overall family functioning, ascertained using self-report, family member reports or clinician reports of overall family functioning, or specific characteristics of family interaction (e.g., communication), as measured through scales like the McMaster Family Assessment Device or the Family Environment Scale (Epstein 1983; Moos 1986)

6. Treatment dropout will be used as a proxy measure of treatment acceptability, and will be defined by the proportion of participants in treatment and control conditions that provide data at the most immediate post-treatment assessment.

7. Instances of severe aggression or violence will be considered as a type of adverse event (see Christensen 2005). Other types of adverse events (e.g., substance abuse, self-harm) may be considered in updates of this review as data becomes available.

Multiple informants

When data on dyadic adjustment or family functioning are available from multiple family members (e.g., when both partners in a couple report on relationship satisfaction), we will combine data from multiple informants to make use of all available data. This will be done by calculating the simple arithmetic mean of scores (assuming that all family members provide reports on the same scale) and the pooled variance. Exceptions may be where different family members show widely divergent perspectives on relationships, as demonstrated by limited shared variance (i.e., < 50% or \( r = 0.70 \)). In such instances, reports from different family members may be considered in separate analyses. Assuming the most studies will not provide data on shared variance, we will examine the implications of decisions to average across multiple informants through sensitivity analyses.

Timing of outcome assessment

We will examine data from all outcomes at: (a) immediate post-treatment assessments, conducted from 0 to 3 months following the completion of therapy; and (b) follow-up assessments, conducted more than 3 months but less than 12 months following completion of therapy. We will also consider additional and longer periods of follow-up assessment if relevant data are available.
Search methods for identification of studies

We will conduct a systematic search procedure to identify all available relevant evidence. This systematic search procedure will comprise two main strategies including: (1) electronic searches of databases and clinical trials registries; and (2) manual searches of other resources.

Electronic searches

We will perform electronic searches of multiple databases. These databases will include the Cochrane Depression, Anxiety and Neurosis Review Group's Specialised Register (CCDANCTR), which covers relevant RCTs indexed in EMBASE (1974-), MEDLINE (1950-) and PsycINFO (1967-), as well as the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, all years). For a full description of the CCDANCTR, please see Appendix 1.

We will also conduct supplementary searches of the following additional databases:
- Literature in the Health Sciences in Latin America and the Caribbean (LILACS);
- Published International Literature on Traumatic Stress (PILOTS); and
- Web of Science.

We will search the CCDANCTR (Studies and References Register) using the following free-text terms:
- (PTSD or post-trauma* or *trauma* or "stress disorder"* or (combat and disorder*) or (war and neuro*)) AND (couple* or partner* or marriage or marital or husband* or wife or wives* or spous* or family or families or multi-family or conjoint or interpersonal or relations* or (child* and parent*)) AND (*therap* or counsel* or treat* or intervention*).

We will adapt these search terms to conduct analogous searches of additional databases (e.g., PILOTS). We will apply no date or language restrictions. We will also search the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal (http://apps.who.int/trialsearch/) and ClinicalTrials.gov (http://clinicaltrials.gov/) to identify unpublished and/or ongoing studies.

Searching other resources

Handsearching

We will manually search the early editions of key journals to identify potentially relevant studies that may not be indexed in the databases. These key journals will include:
- Journal of Traumatic Stress (1988 - 2000);
- Journal of Family Psychology (1987 - 2000); and

Reference lists

We will also manually screen the reference lists and bibliographies of all included studies to identify other relevant references.

Data collection and analysis

Selection of studies

We will select studies in stages. First, we will screen the titles and abstracts (where available) of all records retrieved to determine potentially eligible studies. Two review authors will screen each record. We will obtain full-text articles of any studies that would appear to meet inclusion criteria, as well as those that cannot be excluded based on title and abstract, for further assessment. Two review authors will independently examine each full-text article in order to confirm eligibility, and disagreement will be resolved through discussion. We will identify any duplicate publications and list them along with the primary publication. We will record and present decisions made during the study selection process, as well as the names and numbers of studies and reasons for exclusion at each stage, in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

Data extraction and management

Following the identification of eligible studies, we will extract data on study characteristics from reports using a piloted, structured data extraction template. Data extraction will endeavour to obtain information (where available) relating to publication details (e.g., country of origin, year of publication), sample characteristics (e.g., age and ethnicity of participants, predominant type of trauma), clinical characteristics (e.g., type of therapy, duration of treatment), methodology (e.g., inclusion/exclusion criteria, timing of follow-up assessments), statistical analyses and results (e.g., strategies for managing non-independent data from family members, group means and standard deviations for primary and secondary outcomes). Two review authors will independently extract data from each study to ensure accuracy.

Main comparisons

Multiple comparisons are planned to evaluate the efficacy of stand-alone couple or family therapies for PTSD compared to relevant control comparators. These include:
1. couple or family therapy versus no treatment;
2. couple or family therapy versus standard care; and
3. couple or family therapy versus structured or non-specific individual psychological therapy.

Additional comparisons are planned to evaluate the efficacy of adjunctive couple or family therapies, additional to primary treatment, relative to controls. These include:
1. couple or family therapy (adjunctive to standard care) versus standard care alone;
2. couple or family therapy (adjunctive to structured or non-specific individual psychological therapies) versus structured or non-specific individual psychological therapies alone.

Additional types of comparisons may be considered as studies become available.

Comparisons involving adjunctive therapies will be limited to control conditions that involve substantively similar primary treatments. As such, we will not consider comparisons between couple or family therapies adjunctive to primary treatment and (a) 'no treatment' controls, and (b) substantively different primary treatments (e.g., cognitive-behavioural therapy versus psychodynamic individual therapy). Where multiple couple or family therapy conditions are compared with control conditions, it is envisaged that the couple or family therapy conditions will be combined (Unit of analysis issues).

Assessment of risk of bias in included studies

Two review authors will independently assess risk of bias associated with each study. Both authors will allocate a judgement of 'High', 'Low' or 'Unclear' risk of bias with regard to several design characteristics that are among the main sources of bias in clinical trials (Higgins 2011b). Disagreements between review authors with regard to classification of studies will be resolved through discussion. In line with available recommendations (Juni 1999), we will assess each source of bias independently.

Random allocation to groups (sequence generation)

It is an eligibility requirement that studies use random allocation to groups. Notwithstanding this, it is envisaged that the level of detail published about randomisation procedures may vary. We will classify studies which provide limited or no detail about randomisation as having unclear risk of bias.

Allocation concealment

Adequate concealment of allocation requires that participants and researchers are kept unaware, and are unable to foresee, the groups to which participants are allocated (Schulz 2002). We will classify studies that lack allocation concealment as having high risk of bias.

Blinding

Blinding can refer to hiding the nature of the intervention delivered from multiple potential groups (e.g., participants, treatment providers, outcome assessors) (Montori 2002), and we will consider the following blinding aspects.

1. Participants and treatment providers: blinding of participants and treatment providers is usually easy to accomplish in studies of pharmacological treatments, but it is rarely feasible for psychological therapies. Accordingly, it is expected that most studies will be classified as having a high risk of bias.

2. Outcome assessors: blinding of outcome assessment will refer to masking of group allocation from outcome assessors (e.g., researchers administering symptom scales). Studies that fail to blind outcome assessors (including studies relying on self-report measures completed by participants) will be classified as having a high risk of bias. Given that blinding of outcomes assessors may vary within studies and across outcomes (e.g., some may be self-reported with other outcomes evaluated using blinded outcome assessors), this characteristic will be assessed separately for each outcome considered in Types of outcome measures.

Incomplete outcome data

According to Higgins 2011b, missing data can be caused by both study exclusions and attrition. Justifiable reasons for exclusions may include identifying (after randomisation) that participants were ineligible for the study. In contrast, participants may be excluded because they did not receive the intended intervention in accordance with the protocol (or for other reasons), which may lead to bias (Higgins 2011b). In case of missing data from attrition, primary studies may report analyses conducted using data from participants providing complete information (i.e., ‘completers only’), or by including data from all participants through use of various missing data strategies. These include recommended strategies based on principles of maximum-likelihood or multiple imputation, as well as older (and potentially biased) forms of imputation including mean imputation and last observation carried forward (LOCF) (Graham 2009).

For the purpose of this review, we will classify studies as having a high risk of bias if they violate any of three principles of intention-to-treat (ITT) analyses described by Higgins 2011b. These are:

1. “keep participants in the intervention groups to which they were randomised, regardless of the intervention they received”;
2. “measure outcome data on all participants”; and
3. “include all randomised participants in the analyses”.

Given that approaches to managing incomplete outcome data (from attrition in particular) may vary within studies and across outcomes, we will assess these approaches separately for each outcome considered in Types of outcome measures.

Selective outcome reporting

Selective outcome reporting refers to the presentation of a limited subset of data or analyses based on the nature (e.g., statistical significance) of results (Hutton 2000). Although there are various issues suggestive of selective outcome reporting (Higgins 2011b), we will classify studies in this review as having high risk of bias if they have protocols or entries in trial registries that list primary or secondary outcomes that differ from those reported in the published results (lacking credible explanation). We will classify stud-
ies that are not associated with published protocols or adequately detailed entries in trial registries as having an unclear risk of bias.

**Measures of treatment effect**

**Dichotomous data**
For evaluation of treatment effects based on dichotomous outcomes (e.g., scores in the clinically significant range on relationship adjustment), we will use the risk ratios (RRs) and associated 95% confidence intervals (CIs).

**Continuous data**
For evaluation of treatment effects based on continuous outcomes we will use the mean differences (MDs), where outcomes are reported on the same scale, or the standardised mean difference (SMDs) where outcomes are reported on different scales. We will obtain SMDs by calculating the difference between raw means and dividing by the pooled variance of treatment and control conditions. We will present 95% CIs around the MDs or SMDs.

**Unit of analysis issues**

**Cluster-randomised trials**
Where a cluster-randomised trial is identified, we will extract the methods used to analyse data, while the inflated standard error approach will be used to adjust standard errors for non-independence of observations (Higgins 2011c). To facilitate this, we will extract the degree of non-independence, as reflected in the intra-class correlation (ICC). Where the ICC is not reported, a value of 0.05 will be assumed.

**Cross-over trials**
Where a cross-over trial is identified, we will consider data from the between-group comparison from the first treatment stage only.

**Studies with multiple treatment groups**
Where multiple couple or family therapy conditions are compared with a ‘no treatment’ or individual intervention control, we will combine the couple or family therapy conditions using the formulae reported by Higgins 2011a. Exceptions may be where a stand-alone couple or family therapy and an adjunctive therapy (alongside another primary treatment) are both compared with an individual therapy condition, and where the adjunctive condition provides a significant additional dosage of therapy (in terms of number of sessions). Rather, we will evaluate stand-alone and adjunctive therapy conditions in separate comparisons (Data extraction and management). Where different groups are involved in the same treatment, but have results reported separately, we will also combine these data.

**Dealing with missing data**

**Missing information about study design and results/statistics**
Information about research design that is not reported in a primary publication will be initially ascertained through examination of duplicate publications. Where informative duplicate publications are unavailable, and where missing data relate to the inclusion criteria or risk of bias (as defined in this review), we will contact the study authors for additional information. We will also seek clarification from the study authors where statistics necessary for the estimation of treatment effects (e.g., standard deviations) are missing.

**Assessment of heterogeneity**

**Clinical heterogeneity**
For studies that are clinically heterogeneous or present insufficient information to facilitate quantitative synthesis, we will present a narrative summary of results.

**Statistical heterogeneity**
We will assess statistical heterogeneity across studies using the $I^2$ statistic, which indicates the percentage of total variability across studies that is due to between-study differences (Huedo-Medina 2006). We will also examine the $\chi^2$ statistic and associated significance test (P value). However, this statistic lacks power to detect true differences (Deeks 2011), and greater emphasis will thus be placed on $I^2$. Although thresholds for $I^2$ are arbitrary, there are overlapping bands that may suggest minor (0% to 40%), moderate (30% to 60%), substantial (50% to 90%), and considerable (75% to 100%)
levels of heterogeneity (Deeks 2011). Interpretation of the I² statistic will be qualified through evaluation of the pattern of variability, and whether all studies indicate beneficial effects of treatment. Where strong evidence of true heterogeneity is present, the pooled effect will be considered as a limited, though 'best available' estimate of the expected magnitude of the treatment effect.

Assessment of reporting biases
We will examine multiple databases to identify published research, while trial registers will be searched to identify unpublished studies. We will use funnel plots and the linear regression test to evaluate publication bias where there are more than $k = 10$ studies available (Egger 1997; Sterne 2011). We will also screen relevant databases and trial registers to identify reports published in a non-English language.

Data synthesis
Two authors will enter data into the Cochrane Collaboration statistical software, Review Manager 2014, and we will employ the random-effects model to provide a weighted estimate of the efficacy of each intervention relative to control. This random-effects model assumes true variability in effect sizes across studies, and estimates both the average effect and degree of variability across studies (Normand 1999). Where there is evidence of true heterogeneity, it may be inappropriate to place inordinate emphasis on a weighted mean effect size (especially if some studies indicate harmful effects) and we will instead interpret the pooled estimates through discussion of statistical diversity of studies.

Subgroup analysis and investigation of heterogeneity
In the case of observed statistical heterogeneity, and where sufficient studies are available, we will pursue subgroup analyses to examine factors explaining between-study variability. We will evaluate potential differences in treatment effects according to the following study characteristics.

1. Disorder-specific versus generic couple or family therapies: Disorder-specific and generic therapies may include additional components of treatment targeting individual psychopathology, and may thus have greater impacts on individual post-traumatic symptoms. The more singular focus of generic therapies on relationship problems may lead to larger improvements in couple and family adjustment.

2. Nature of trauma linked to disorder onset: Patients exposed to interpersonal trauma (e.g., sexual assault) may demonstrate greater severity of problems in couple and family functioning, relative to traumas that do not have equivalent interpersonal components (e.g., combat exposure, natural disasters). Accordingly, disorders associated with interpersonal trauma may benefit more from couple and family therapies.

3. Recent onset versus chronic PTSD: Disorders with recent onset (e.g., within one year of trauma exposure) may be more amenable to change following couple and family therapies for PTSD, relative to longer-standing conditions where symptoms and interpersonal patterns have become established over time. We will conduct the above subgroup analyses using the approach described by Deeks 2011, applying the test for subgroup differences available in Review Manager 2014. We may consider other potential clinical characteristics (e.g., couple versus family-based therapies for PTSD) in updates as studies and literature becomes available.

Sensitivity analysis
We will conduct sensitivity analyses to examine whether findings are robust to approaches adopted in this review (Deeks 2011). We will consider the following characteristics of assumptions sequentially for the purposes of these analyses.

- Where outcome data from multiple informants are available, we will exclude data from family members.
- We will exclude cluster randomised trials.
- We will vary the ICC used during analyses of cluster randomised trials.
- We will exclude cross-over trials.
- Results based on 'completers only' will be excluded.
- Results based on imputed values for missing data will be imputed.

Summary of findings table
Summary of findings tables will be developed to summarise the key findings of the review, for all relevant populations, in line with Schünemann 2011. The tables will present findings relating to each type of intervention in terms of primary and secondary outcomes (Types of outcome measures), standardised effect size estimates (and 95% CIs) to illustrate comparative risk, the number of studies and participants, and the quality of evidence based on standards of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group (Balshem 2011).

Acknowledgements

Funding
The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Depression, Anxiety and Neurosis Group.
Disclaimer
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.

REFERENCES

Additional references

American Psychiatric Association 2000

American Psychiatric Association 2013

Balshem 2011

Baucom 1998

Beck 1961

Beck 1988

Bisson 2007

Blake 1995

Brown-Bowers 2012

Christensen 2004

Christensen 2005

Cloitre 1997

Coulter 2013

Davis 2000

Deeks 2011

Dirkzwager 2003

Egger 1997

Epstein 1983
Couple and family therapies for post-traumatic stress disorder (PTSD) (Protocol)

Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Erbes 2008
Erbes CR, Polusny MA, MacDermin S, Compton JS.

Evans 2009

Evans 2010
Evans L, Cowlishaw S, Forbes D, Parslow R, Lewis V.

Figley 1988

Foa 1993

Frasure-Smith 2000

Freedland 2011
Freedland KE, Mohr DC, Davidson KW, Schwartz JE.

Friedman 2011
Friedman MJ, Resick PA, Bryant RA, Brewin CR.

Galovski 2004

Gillies 2012
Gillies D, Taylor F, Gray C, O'Brien L, D'Abrew N.

Glass 1992

Glenn 2002

Goff 2007

Graham 2009

Hetrick 2010

Higgins 2011a

Higgins 2011b

Higgins 2011c

Huedo-Medina 2006

Hutton 2000

Johnson 1998

Jordan 1992
Jordan KB, Marmar CR, Fairbank JA, Schlenger WE, Kulka RA, Hough RL, et al. Problems in families of male...

**Juni 1999**


**Kaniasty 2008**


**Kessler 1995**


**Krause 2006**


**Lamoureux 2012**


**Laurenceau 1998**

Laurenceau J, Barrett LF, Pietromonaco PR. Intimacy as an Theory, Research, Practice, and Policy

**Locke 1959**


**Madanes 1986**


**Minuchin 1974**


**Mohr 2009**


**Monson 2004**


**Monson 2009**


**Montori 2002**


**Moos 1986**


**Mueser 1995**


**Normand 1999**


**Orcutt 2004**


**Regier 2013**


**Review Manager 2014** (Computer program)


**Riggs 2009**


**Roberts 2009**

Rose 2002

Sautter 2009

Schulz 2002

Schünemann 2011

Snyder 1989

Snyder 2006

Solomon 2006

Spanier 1976

Sprinkle 2004

Stein 2006

Sterne 2011

Taft 2007a

Taft 2007b

Taft 2009

Taft 2011

Tarrier 1999

von Bertalanffy 1969

Ware 2000

Weathers 1993

Weathers 2001
WHO 2010


* Indicates the major publication for the study

APPENDICES

Appendix 1. Further information on CCDANCTR

The Cochrane Depression, Anxiety and Neurosis Group (CCDAN) maintain two clinical trials registers at their editorial base in Bristol, UK, a references register and a studies based register. The CCDANCTR-References Register contains over 33,000 reports of randomised controlled trials in depression, anxiety and neurosis. Approximately 60% of these references have been tagged to individual, coded trials. The coded trials are held in the CCDANCTR-Studies Register and records are linked between the two registers through the use of unique Study ID tags. Coding of trials is based on the EU-Psi coding manual. Please contact the CCDAN Trials Search Coordinator for further details. Reports of trials for inclusion in the Group's registers are collated from routine (weekly), generic searches of MEDLINE (1950-), EMBASE (1974-) and PsycINFO (1967-); quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review specific searches of additional databases. Reports of trials are also retrieved from WHO ICTRP search portal, ClinicalTrials.gov, drug companies, the hand-searching of key journals, conference proceedings and other (non-Cochrane) systematic reviews and meta-analyses. Details of CCDAN's generic search strategies can be found on the Group's website. The CCDANCTR is hosted and maintained on the new Cochrane Register of Studies (CRS) meta-register, which allows for left- and right-hand truncation of search terms.

CONTRIBUTIONS OF AUTHORS

Sean Cowlishaw conceptualised the review. Sean Cowlishaw, Lynette Evans, Aino Suomi and Bryan Rodgers all contributed to the development of the protocol. All authors will contribute to the conduct and writing of the review.

DECLARATIONS OF INTEREST

The authors have no conflicts of interest to declare.

SOURCES OF SUPPORT
Internal sources

- University of Bristol, UK.
  Salary support (SC)
- La Trobe University, Australia.
  Salary support (LE)
- Australian National University, Australia.
  Salary support (AS, BR)

External sources

- National Health & Medical Research Council, Australia.
  BR receives salary support from National Health & Medical Research Council (Fellowship No. 471429).